Drug intelligence / Profile preview

SAL0139

Development stage: Unknown
Lead developer: Shenzhen Salubris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

SAL0139 is an innovative small-molecule drug developed by Shenzhen Salubris Pharmaceuticals for the treatment of dyslipidemia (hyperlipidemia). Formulated as an oral tablet, SAL0139 has demonstrated the potential to reduce low-density lipoprotein cholesterol (LDL-C) in preclinical studies. It has received clinical trial approval from China's National Medical Products Administration (NMPA) and is currently in Phase 1 clinical development. The drug aims to provide a new therapeutic option for managing cardiovascular disease risk associated with elevated lipid levels.

Beyond the preview

Go deeper on SAL0139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAL0139.

Explore the full profile